RESUMEN
The aim of this study was to investigate a possible interrelation between bronchial hyperreactivity and psychological hyperreactivity. In order to record changes in both bronchial and psychological reactions throughout the menstrual cycle, 10 women out-patients with moderate asthma were followed up for six months, and their physical and psychological status as well as their reactions to life-events and environmental influences were assessed through self-reporting measures and weekly psychotherapeutic sessions. Psychotherapy was used both as a supplement to the medical treatment and as a method of data collection. A relationship between lowered resistance to stress, lowered resistance to infections and increased bronchial hyperreactivity is suggested as background aetiological factors for the exacerbation of asthma around menstruation.
Asunto(s)
Asma/psicología , Hiperreactividad Bronquial/psicología , Menstruación/psicología , Adulto , Nivel de Alerta , Asma/terapia , Femenino , Humanos , Inventario de Personalidad , Síndrome Premenstrual/psicología , Factores de RiesgoRESUMEN
The purpose of this randomized patient- and observer-blinded cross-over trial was to evaluate the efficacy of chiropractic treatment in the management of chronic asthma when combined with pharmaceutical maintenance therapy. The trial was conducted at the National University Hospital's Out-patient Clinic in Copenhagen, Denmark. Thirty-one patients aged 18-44 years participated, all suffering from chronic asthma controlled by bronchodilators and/or inhaled steroids. Patients, or who had received chiropractic treatment for asthma within the last 5 years, who received oral steroids and immunotherapy, were not eligible. Patients were randomized to receive either active chiropractic spinal manipulative treatment or sham chiropractic spinal manipulative treatment twice weekly for 4 weeks, and then crossed over to the alternative treatment for another 4 weeks. Both phases were preceded and followed by a 2-week period without chiropractic treatment. The main outcome measurements were forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), daily use of inhaled bronchodilators, patient-rated asthma severity and non-specific bronchial reactivity (n-BR). Using the cross-over analysis, no clinically important or statistically significant differences were found between the active and sham chiropractic interventions on any of the main or secondary outcome measures. Objective lung function did not change during the study, but over the course of the study, non-specific bronchial hyperreactivity (n-BR) improved by 36% (P = 0.01) and patient-rated asthma severity decreased by 34% (P = 0.0002) compared with the baseline values.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Asma/terapia , Quiropráctica , Adolescente , Adulto , Asma/fisiopatología , Broncodilatadores/uso terapéutico , Quiropráctica/métodos , Enfermedad Crónica , Estudios Cruzados , Método Doble Ciego , Quimioterapia Combinada , Femenino , Volumen Espiratorio Forzado/fisiología , Glucocorticoides/uso terapéutico , Humanos , Pulmón/fisiología , Masculino , Capacidad Vital/fisiologíaRESUMEN
BACKGROUND: High dose inhaled glucocorticosteroids are increasingly used in the management of patients with moderate to severe asthma. Although effective, they may cause systemic side effects. Fluticasone propionate is a topically active inhaled glucocorticosteroid which has few systemic effects at high doses. METHODS: Fluticasone propionate, 1.5 mg per day, was compared with beclomethasone dipropionate at the same dose for one year in patients with symptomatic moderate to severe asthma; 142 patients received fluticasone propionate and 132 received beclomethasone dipropionate. The study was multicentre, double blind and of a parallel design. For the first three months patients attended the clinic every four weeks and completed daily diary cards. For the next nine months they were only seen at three monthly intervals in the clinic. RESULTS: During the first three months diary card peak expiratory flow (PEF) rate and lung function measurements in the clinic showed significantly greater improvement in patients receiving fluticasone propionate (difference in morning PEF 15 l/min (95% CI 6 to 25)), and these differences were apparent at the end of the first week. The improved lung function was maintained throughout the 12 month period and the number of severe exacerbations in patients receiving fluticasone propionate was reduced by 8% compared with those receiving beclomethasone dipropionate. No significant differences between the two groups were observed in morning plasma cortisol levels, urinary free cortisol levels, or response to synthetic ACTH stimulation. In addition, both the rates of withdrawal and of adverse events were low, and there were fewer exacerbations of asthma with fluticasone propionate than beclomethasone dipropionate. CONCLUSIONS: This study shows that fluticasone propionate in a daily dose of 1.5 mg results in a significantly greater increase in PEF and asthma control than the same dose of beclomethasone dipropionate, with no increase in systemic or other side effects.
Asunto(s)
Androstadienos/uso terapéutico , Antiinflamatorios/uso terapéutico , Asma/tratamiento farmacológico , Beclometasona/uso terapéutico , Administración Tópica , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Androstadienos/efectos adversos , Antiinflamatorios/efectos adversos , Asma/sangre , Asma/fisiopatología , Beclometasona/efectos adversos , Método Doble Ciego , Femenino , Fluticasona , Humanos , Hidrocortisona/sangre , Pulmón/fisiopatología , Masculino , Persona de Mediana Edad , Ápice del Flujo Espiratorio/efectos de los fármacosRESUMEN
The effects of high-dose inhaled budesonide (800 micrograms twice daily) and those of inhaled beclomethasone dipropionate (750 micrograms twice daily) were compared with respect to lung function, symptoms, bronchial reactivity and adrenocortical function in a doubleblind, double-dummy cross-over study. The subjects were 40 adult patients suffering from either allergic or non-allergic asthma. The asthma was categorized as moderate to severe, and the asthma was insufficiently controlled on inhalational steroids given in doses of 300 to 500 micrograms daily. After a two week "run-in" period the patients were randomized to six weeks treatment with either budesonide or beclomethasone dipropionate, followed by six weeks treatment with the opposite drug. Both inhaled budesonide and inhaled beclomethasone dipropionate were able to improve objective measures of lung function and bronchial sensitivity to histamine. Neither drug affected adrenocortical function, and no serious side-effects were noted during the trial. It is concluded that budesonide and beclomethasone dipropionate are safe and effective drugs for the treatment of asthma in adults. The substances are equally effective taken microgram for microgram.
Asunto(s)
Corteza Suprarrenal/efectos de los fármacos , Asma/tratamiento farmacológico , Beclometasona/administración & dosificación , Bronquios/efectos de los fármacos , Pulmón/efectos de los fármacos , Pregnenodionas/administración & dosificación , Administración por Inhalación , Adolescente , Adulto , Asma/diagnóstico , Asma/fisiopatología , Beclometasona/efectos adversos , Broncodilatadores/administración & dosificación , Broncodilatadores/efectos adversos , Budesonida , Método Doble Ciego , Evaluación de Medicamentos , Femenino , Volumen Espiratorio Forzado , Humanos , Masculino , Persona de Mediana Edad , Ápice del Flujo Espiratorio , Pregnenodionas/efectos adversosRESUMEN
Based on a 3-year prospective study of 20 pollen-allergic patients, where a detailed analysis of the IgE, IgG1 and IgG4 immune response was performed, we propose that a common regulatory mechanism exists between the IgE and IgG1 synthesis and between IgE and IgG4 synthesis during immunotherapy. It was found that the IgE immune response to a number of antigens was quantitatively diminished during the period of immunotherapy when IgG1 was present early (week 12), and for other antigens there was a rise in IgE without an early IgG1 antibody response. Additionally, it was found that for some antigens a rise in IgE antibodies was contrasted by a fall in the IgG4 antibody response and for other antigens the opposite was true, indicating a regulatory mechanism between the IgE and the IgG4 synthesis. A statistical analysis showed that these findings were statistically significant at the 0.01% level for the IgE/IgG1 relationship and at the 0.05% level for the IgE/IgG4 relationship. These findings could have implications for future immunotherapy regimens.
Asunto(s)
Desensibilización Inmunológica , Hipersensibilidad/inmunología , Inmunoglobulina E/inmunología , Inmunoglobulina G/inmunología , Humanos , Hipersensibilidad/terapia , Inmunoglobulina E/biosíntesis , Inmunoglobulina E/clasificación , Inmunoglobulina G/biosíntesis , Inmunoglobulina G/clasificación , Polen/inmunología , Estudios ProspectivosRESUMEN
The efficacy of budesonide (800 micrograms b.d.) and beclomethasone dipropionate (750 micrograms b.d.) in controlling the symptoms of asthma, pulmonary function, bronchial responsiveness to histamine, and adrenal function, was assessed in a double-blind, double-dummy cross-over study of 36 adult chronic asthmatic patients. The patients, the majority of whom were assessed to be affected to a severe degree, were insufficiently controlled in their current regimen of inhaled steroids and/or inhaled and oral bronchodilators. A 2 weeks baseline period preceded 6 weeks of treatment with each of the study drugs. Both treatment groups showed improvements from baseline in clinical assessment of lung function carried out after the first 6 weeks of treatment. No significant differences were seen throughout the entire 12 weeks study, when comparing the effects of the treatments on FEV1, FVC, PEF or the histamine PC20. Asthma severity, symptom score and inhaled bronchodilator use showed the same results after both treatments. It is concluded that inhalations of budesonide and beclomethasone dipropionate in high doses are equally potent in the treatment of severe asthma. There is no significant influence on the adrenal function and no significant side effects during a period equal to that of the present study.
Asunto(s)
Glándulas Suprarrenales/fisiología , Asma/tratamiento farmacológico , Beclometasona/uso terapéutico , Hiperreactividad Bronquial/tratamiento farmacológico , Broncodilatadores/uso terapéutico , Pregnenodionas/uso terapéutico , Administración por Inhalación , Adolescente , Glándulas Suprarrenales/efectos de los fármacos , Adulto , Asma/fisiopatología , Beclometasona/administración & dosificación , Hiperreactividad Bronquial/fisiopatología , Broncodilatadores/administración & dosificación , Budesonida , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Modelos Estadísticos , Pregnenodionas/administración & dosificación , Mecánica RespiratoriaRESUMEN
The effect of treatment with astemizole (Hismanal) on symptoms elicited by ingestion of hazelnuts in birch pollen-allergic patients (the oral allergy syndrome) was investigated. Thirty patients with a well-documented allergy to silver birch, experiencing symptoms when ingesting hazelnuts, were included in the study. All had a positive skin prick test (SPT) to birch, whereas 29 and 27, respectively, showed a positive RAST and basophil histamine release test (HR) to birch. In contrast, only 15 patients had a positive SPT to hazelnut, 13 had a positive RAST, whereas 24 had a positive HR. After two oral provocations with hazelnuts the patients were randomized to receive either 10 mg of astemizole or placebo daily for 2 weeks in a double blind protocol followed by two oral provocations. Treatment with astemizole significantly reduced the symptoms compared with placebo (P = 0.004); however, without completely abolishing the symptoms.
Asunto(s)
Astemizol/uso terapéutico , Edema/tratamiento farmacológico , Hipersensibilidad a los Alimentos/tratamiento farmacológico , Enfermedades de la Boca/tratamiento farmacológico , Nueces/efectos adversos , Enfermedades Faríngeas/tratamiento farmacológico , Reacciones Cruzadas , Método Doble Ciego , Edema/etiología , Liberación de Histamina , Humanos , Enfermedades de la Boca/etiología , Enfermedades Faríngeas/etiología , Polen , Prueba de RadioalergoadsorciónRESUMEN
It is an elegant treatment of IgE allergic inflammation in the airways. It must be started very early in the allergic disease together with allergen avoidance, prevention, optimal symptomatic and antiinflammatory treatment and general health care.
Asunto(s)
Asma/terapia , Desensibilización Inmunológica , Alérgenos/uso terapéutico , Desensibilización Inmunológica/efectos adversos , Europa (Continente)/epidemiología , HumanosRESUMEN
In 30 stable asthmatics, a comparison was made between the changes in pulmonary function (FEV1, FVC, PEF, MEF75, MEF50 and MEF25) hourly for 9 h after a single dose of inhaled budesonide 1,600 micrograms, and placebo. All subjects used inhaled steroids daily; this medication was, however, withheld 8 days prior to the study. For all parameters of pulmonary function, a significant difference in favour of budesonide was demonstrated. The effect tended to decrease after 9 h, and had abated within 24 h. FEV1 age, sex, smoking habits, or results of an inhaled beta 2-agonist reversibility test could not be demonstrated as predictors of those subjects to react with the most pronounced responses to budesonide. In conclusion, our results demonstrate an effect 3 h after administration of an inhaled glucocorticosteroid in adult outpatients with chronic asthma. These results parallel previous findings in highly selected asthmatics and after systemic administration of glucocorticosteroids. Single-dose administration and subsequent monitoring for 8-9 h may therefore prove valuable in evaluating new prophylactic agents for the treatment of asthma.
Asunto(s)
Asma/tratamiento farmacológico , Broncodilatadores/administración & dosificación , Pregnenodionas/administración & dosificación , Administración por Inhalación , Adulto , Asma/fisiopatología , Budesonida , Enfermedad Crónica , Método Doble Ciego , Femenino , Volumen Espiratorio Forzado/efectos de los fármacos , Humanos , Masculino , Persona de Mediana EdadRESUMEN
In a previous study guinea pigs inbred for their ability to develop respiratory anaphylaxis to experimental antigens have been used for comparison of different forms of immunotherapy (IT). Passive, active and combined (immune complexes prepared from antigen and specific IgG) IT was compared with placebo. In the present study methods were evaluated for determination of the allergen-specific IgE and IgG. IgE was determined by the passive cutaneous anaphylactic test (PCA) and the variability of this test on different strains of the recipient guinea pig was investigated. The same strain as used for the IT study was found to produce the most potent response. Radioimmunometric assays (RIA) were developed and validated for determination of specific IgG1 and IgG2. The IgE and IgG immune response in animals from the IT study were then evaluated by means of PCA and RIA. Animals from all four treatment groups were sensitized during the first part of the IT study, and responded with a marked IgE synthesis which later stabilized on a more moderate level. In spite of notably reduced symptoms in groups treated with active and combined IT, no difference in the IgE level was found between the four groups. In contrast to IgE, mean group titers of IgG1 and IgG2 in the groups receiving active or combined IT rose drastically during the first part of therapy and closely paralleled the clinical response during the rest of the study period. However, in the individual animals, no correlations were found between immune response and clinical symptoms. Thus, the strong IgG response during immunotherapy may not be causally related to the outcome of treatment.
Asunto(s)
Complejo Antígeno-Anticuerpo/inmunología , Asma/terapia , Inmunoglobulina E/análisis , Inmunoterapia , Animales , Asma/inmunología , Pruebas de Provocación Bronquial , Cobayas , Inmunoglobulina G/análisis , Ensayo Inmunorradiométrico , Anafilaxis Cutánea Pasiva/inmunologíaRESUMEN
The study was conducted to investigate whether introduction of histamine in enterosoluble capsules produced the same amount of urinary histamine metabolites as that found after application of histamine through a duodeno-jejunal tube. Secondly, to examine whether a histamine-restrictive or a fast diet affected the amount of urinary metabolites. Fifteen healthy subjects were challenged four times with 100 mg of histamine. Results were monitored by the urinary recovery of 1,4-methylimidazole acetic acid (MIAA) from 24 h before to 72 h after challenge. Urine was collected in 24-h samples except on the first day after challenge when separation into 0-2h-, 2-4 h- and 4-24 h-fractions was made. MIAA was measured by high performance liquid chromatography (HPLC). The results showed that during the first 2 h after challenge the recovery of MIAA was higher with tubes than with capsules. Measurements from all other intervals did not differ significantly between the two challenge regimens. Fast (water only) and histamine-restrictive diet versus non-restrictive diet did not affect the urinary MIAA. MIAA was significantly higher overall during the first 24 h after challenge than in any other fraction. We conclude that oral administration of enterosoluble capsules is an easy and appropriate method for intestinal histamine challenge. Fast and histamine-restrictive diets are not necessary, but subjects should record unexpected responses in a food and symptom diary.
Asunto(s)
Hipersensibilidad a los Alimentos/diagnóstico , Histamina/administración & dosificación , Adolescente , Adulto , Cápsulas , Dieta , Ayuno , Femenino , Humanos , Imidazoles/orina , Intubación Gastrointestinal , Masculino , Persona de Mediana EdadAsunto(s)
Asma/terapia , Inmunoterapia/tendencias , Alérgenos/normas , Humanos , Inmunoterapia/métodos , Inmunoterapia/normasRESUMEN
Detailed evaluation of the IgE and IgG-subclass immune response during immunotherapy can now be performed by crossed radio immunoelectrophoresis (CRIE). Some new concepts are introduced facilitating the handling of the vast amount of data obtained by quantitating the immune response. These concepts are "distance" between antibody responses and "immune response width". The 20 patients included in this study were pollen-allergic patients who underwent specific immunotherapy in a 3-year prospective study. It was found that the immune response during immunotherapy was restricted to IgG1 and IgG4 antibodies. The semi-quantitative CRIE analysis correlated with the RAST analysis for the IgE samples before start of immunotherapy, for the IgG1 samples at week 12, and for all the IgG4 samples. During immunotherapy the number of IgG1 antibodies directed to the different antigens increased towards 11 antigens and decreased towards six. For the IgG4 antibodies the number of reactions increased towards 15 antigens and decreased towards four. The increase is generally paralleled by an increase in quantitative immune response as well. For some of the antigens a rise in the IgE antibodies is contrasted by a fall in the IgG4 antibody response, and for other antigens the opposite was true, indicating a regulatory mechanism between the IgE and the IgG4 synthesis. The IgE immune response to a number of antigens, including the major allergens before the start of immunotherapy, was quantitatively diminished during the period of immunotherapy when IgG1 was present early (week 12) in the period, and for other antigens there was a rise in IgE without an early IgG1 antibody response. This suggests that IgG1 can have a regulating influence on the IgE synthesis. Finally, we have found that IgE antibodies with specificities not present in the samples taken before immunotherapy were formed during immunotherapy. These new IgE antibodies do not, however, seem to impair the outcome of treatment.
Asunto(s)
Inmunoglobulina E/biosíntesis , Inmunoglobulina G/biosíntesis , Inmunoterapia , Rinitis Alérgica Estacional/inmunología , Antígenos/inmunología , Humanos , Inmunoelectroforesis Bidimensional , Inmunoglobulina E/clasificación , Inmunoglobulina G/clasificación , Polen/inmunología , Estudios ProspectivosRESUMEN
The formation of specific IgE, IgG1, and IgG4 antibodies was investigated by immunoblotting during hyposensitization with timothy grass-pollen extract and 6 years later, Until the end of immunotherapy, specific IgG antibody levels increased. Also simultaneously, the number of allergenic components detected by IgG increased. However, this IgG response was similar in responding and nonresponding patients; thus, it did not correlate with the clinical outcome of the therapy. More allergenic compounds were also detected by IgE on immunoblots, but again without correlation to success of therapy. Six years after immunotherapy, the therapeutic effect was still present, although by now the observed immunoglobulin-binding patterns were similar to patterns observed in the same patients' sera collected before the initiation of hyposensitization. Thus, changes of antibody-binding patterns in immunoblot do not relate to the success or failure of immunotherapy.
Asunto(s)
Hipersensibilidad/terapia , Alérgenos/inmunología , Desensibilización Inmunológica , Estudios de Seguimiento , Humanos , Immunoblotting , Inmunoglobulina E/metabolismo , Inmunoglobulina G/metabolismo , Inmunoterapia , Unión Proteica , Factores de TiempoRESUMEN
This multicentre, double-blind, randomized parallel-group study compared 3 weeks' treatment with either loratadine (Clarityn) 10 mg once daily, or clemastine (Tavegyl) 1 mg twice daily, and placebo in outpatients with active perennial allergic rhinitis. 155 patients were evaluated for efficacy and safety. Grading of four nasal and three non-nasal symptoms, rhinoscopy signs, and therapeutic response was performed on treatment days 6, 13, and 20. Patients recorded daily symptoms and possible adverse experiences in a diary, also indicating when symptoms of active rhinitis were relieved. Loratadine and clemastine were statistically significantly superior to placebo throughout the study (P less than 0.05), based on assessment of patients' nasal and eye symptoms, patients' diary scores, rhinoscopy signs of symptoms, and onset of relief. The loratadine group showed a statistically significantly (P less than 0.05) faster onset of relief of symptoms compared with the group treated with clemastine. Concerning nasal stuffiness, loratadine was significantly (P less than 0.05) superior to clemastine after 1 week's treatment. Reports of adverse reactions showed that significantly (P less than 0.05) more patients complained of sedation in the clemastine than in the loratadine group. Regarding other adverse experiences and laboratory tests, the three treatment groups were statistically comparable (P less than 0.05). The study showed that compared with placebo both loratadine and clemastine were effective in relieving nasal and eye symptoms in patients with perennial allergic rhinitis. Loratadine was safe and well tolerated and was significantly less sedative than clemastine; loratadine may therefore possess an advantage in clinical use in the treatment of perennial allergic rhinitis.
Asunto(s)
Clemastina/uso terapéutico , Ciproheptadina/análogos & derivados , Antagonistas de los Receptores Histamínicos/uso terapéutico , Pirrolidinas/uso terapéutico , Rinitis Alérgica Perenne/tratamiento farmacológico , Adolescente , Adulto , Anciano , Clemastina/administración & dosificación , Clemastina/efectos adversos , Ciproheptadina/administración & dosificación , Ciproheptadina/uso terapéutico , Método Doble Ciego , Femenino , Antagonistas de los Receptores Histamínicos/administración & dosificación , Humanos , Loratadina , Masculino , Registros Médicos , Persona de Mediana Edad , Estudios Multicéntricos como Asunto , Ensayos Clínicos Controlados Aleatorios como Asunto , Factores de TiempoRESUMEN
Methylprednisolone pulse therapy (MPPT) has been shown to possess a long-lasting effect in other immune-inflammatory diseases without the well-known side effects caused by long-term treatment with glucocorticosteroids. In an attempt to reduce the long-term use of oral steroids in asthmatics, we conducted this double-blind, double-dummy study to compare the use of MPPT (1 g of methylprednisolone intravenously) (8 patients) with a short course of oral prednisolone (10 patients) in asthmatics presenting with acute severe asthma. Both treatments were effective in relieving the acute attack of asthma. The MPPT-treated patients did not show a faster resolution than did the orally treated group. No patients needed assisted ventilation, and no deaths occurred. One week after the treatment FEV1 tended to decrease in the methylprednisolone group compared with the oral prednisolone group (P = 0.06). The patients initially receiving MPPT needed supplementary prednisolone earlier and in higher doses than did the patients receiving oral prednisolone as initial treatment. At the end of the 12 weeks' study period, the groups reached identical FEV1. In conclusion, we did not find intravenous methylprednisolone superior to oral prednisolone in the treatment of acute attacks of severe asthma, but methylprednisolone pulse therapy had a shorter duration as regards protection against future asthma attacks.
Asunto(s)
Asma/tratamiento farmacológico , Metilprednisolona/uso terapéutico , Prednisolona/uso terapéutico , Enfermedad Aguda , Administración Oral , Método Doble Ciego , Estudios de Seguimiento , Humanos , Infusiones Intravenosas , Metilprednisolona/administración & dosificación , Ensayos Clínicos Controlados Aleatorios como AsuntoRESUMEN
A double-blind study on hyposensitization (HS) with two extracts prepared from the house dust mite Dermatophagoides pteronyssinus (Dp) was performed on a group of asthmatics with bronchial sensitivity to Dp. In 18 patients, aluminium-hydroxide was added to the Dp-extract to give a depot effect (Dp-group). Nineteen patients were treated with a similar extract in which allergenicity had been reduced by coupling to monomethoxypolyethylene glycol (mPEG-Dp-group). This extract had previously been shown to have less effect on clinical symptoms and skin sensitivity compared to the Dp-extract. In the Dp- and mPEG-Dp-groups, 778 and 675 injections were administered. Fifteen and 12 patients in the Dp- and mPEG-Dp-groups had systemic reactions (P greater than 0.05). The frequency of injections giving systemic reactions was reduced in the mPEG-Dp-group: 5.1% compared to 9.0% in the Dp-group (P less than 0.01). In the mPEG-Dp-group, reactions were mild to moderate, mainly late-occurring asthma and urticaria, whereas two episodes of anaphylaxis and four of severe asthma occurred in the Dp-group. The reduction in side effects seems promising, but a further dose increase in the mPEG-Dp-group would be necessary to compare the side effects of doses with equal therapeutic effectiveness. High frequency of late local reactions made dose increase impossible with the present slightly modified extract. The systemic side effects occurred more frequently in patients highly skin test-sensitive to Dp prior to treatment. All patients skin test-positive to less than or equal to 100 BU had systemic reactions. Systemic side effects could not be predicted from the size of previous local reactions.
Asunto(s)
Asma/terapia , Desensibilización Inmunológica/efectos adversos , Polvo/efectos adversos , Ácaros/inmunología , Polietilenglicoles/efectos adversos , Animales , Asma/inmunología , Desensibilización Inmunológica/métodos , Relación Dosis-Respuesta Inmunológica , Método Doble Ciego , Humanos , Hipersensibilidad Tardía/inmunología , Inyecciones Subcutáneas , Polietilenglicoles/administración & dosificación , Factores de TiempoRESUMEN
Seventeen patients with perennial asthma, stable on a moderate dose of inhaled steroid, participated in a crossover study comparing the clinical effect of a non-sedative, potent and highly selective H1 antagonist (loratadine 10 mg) with placebo. Each treatment period began with 2 weeks run-in followed by 8 weeks on either antihistamine or placebo. During the 8-week periods inhaled steroid was gradually tapered according to a fixed scheme. One patient was withdrawn from active treatment and three from placebo periods because of decreasing lung function (P greater than 0.1). Among the remaining 13 patients there was a threefold (1.8-4.8) decrease in the bronchial sensitivity to histamine during treatment with antihistamine compared to placebo (P less than 0.01). There was a trend in favour of active treatment with regard to changes in all symptom scores, lung function and use of escape medication, but these differences were not statistically significant. The increase in FEV1 was less than 5% of predicted normal (P less than 0.05). We concluded that the bronchial response to histamine can be attenuated by loratadine, an oral H1 receptor antagonist, but further studies are necessary to assess the clinical usefulness and place of loratadine in the therapy of asthma.
Asunto(s)
Asma/tratamiento farmacológico , Ciproheptadina/análogos & derivados , Adulto , Asma/fisiopatología , Bronquios/fisiopatología , Ensayos Clínicos como Asunto , Ciproheptadina/uso terapéutico , Método Doble Ciego , Femenino , Volumen Espiratorio Forzado , Histamina , Antagonistas de los Receptores Histamínicos , Humanos , Loratadina , Masculino , Persona de Mediana Edad , Ápice del Flujo EspiratorioRESUMEN
After a 2-week run-in period 23 atopics and non-atopics with perennial rhinitis were treated with intranasally nebulized aqueous flunisolide or aqueous beclomethasone dipropionate in a randomized, double-blind cross-over study, each treatment period being 4 weeks. Before and after each treatment period daily rhinitis symptoms were recorded, and additional determination of nasal airway resistance was performed by posterior rhinomanometry. No statistically significant difference between drugs was observed for any effect parameter recorded, and furthermore no difference in patient preference for either drug was found. It is concluded that both steroids are effective for the improvement of nasal airway in patients with perennial, atopic and non-atopic rhinitis.